MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:38Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Macrolide antibiotics]]
			[[Category:Antibacterials]]
			[[Category:Prokinetics]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #235

2026-05-23T04:04:20Z

parser-claude batch MedTemplate pre-fill, Top 300 #235

New page

{{MedTemplate
| generic = Erythromycin
| brand = E.E.S., EryPed, Ery-Tab, PCE, Erythrocin (lactobionate IV); topical Erygel, Akne-Mycin; ophthalmic ointment
| structure =
| classes = [[:Category:Macrolide_antibiotics|Macrolide antibiotic]], [[:Category:Antibacterials|Antibacterial]], [[:Category:Prokinetics|Prokinetic (off-label)]]
| uses = <vote slug="atypical-pneumonia-use">Atypical pneumonia (Mycoplasma, Legionella, Chlamydophila)</vote>, <vote slug="strep-throat-pcn-allergic-use">Streptococcal pharyngitis (penicillin-allergic)</vote>, <vote slug="pertussis-use">Pertussis treatment and prophylaxis</vote>, <vote slug="acne-vulgaris-topical-use">Inflammatory acne (topical)</vote>, <vote slug="gastroparesis-prokinetic-use">Gastroparesis (off-label, low-dose prokinetic)</vote>, <vote slug="newborn-eye-prophylaxis-use">Neonatal ophthalmia prophylaxis (topical ointment)</vote>
| starting_dose = 250-500 mg PO QID; 7.5-12.5 mg/kg IV q6h; topical and ophthalmic per formulation
| preparations = 250, 500 mg base or stearate tablets; ER tablets; ethyl succinate 200 mg/5 mL suspension; 500 mg, 1 g IV (lactobionate); 2% topical solution/gel; 0.5% ophthalmic ointment
| fda_max = 4 g/d (rarely tolerated due to GI effects)
| pill_id =
| routes = Oral, IV, topical, ophthalmic
| onset = Hours
| duration = 6-8 hours
| halflife = ~1.5-2 hours<ref name="ery-tab-label">FDA Prescribing Information, Ery-Tab (erythromycin), Arbor Pharmaceuticals, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050207s058lbl.pdf</ref>
| bioavailability = ~30-65% (oral; acid-labile, hence enteric-coated formulations; food affects absorption variably)<ref name="ery-tab-label" />
| pregnancy = Generally considered safe; commonly used in pregnancy.{{citation needed}}
| legal = OTC (ophthalmic ointment) and [[USLegal:Prescription only|Rx-only]] (other forms) in US
| mechanism = <vote slug="erythromycin-mech-claim">Erythromycin reversibly binds the 23S rRNA of the bacterial 50S ribosomal subunit, blocking peptide chain translocation and inhibiting protein synthesis.</vote> The prokinetic effect is mechanistically distinct: erythromycin agonizes motilin receptors on GI smooth muscle, triggering migratory motor complexes — a property exploited in gastroparesis (often tachyphylactic). '''QT-interval prolongation''' and significant CYP3A4 inhibition (statins, calcineurin inhibitors, warfarin, theophylline) limit modern systemic use compared with azithromycin and clarithromycin<ref name="ery-tab-label" />.
}}

== References ==
<references />

Erythromycin - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #235